氨曲南-阿维巴坦药敏试验:商业梯度扩散与纸片扩散法的对比评估
该研究在两家独立临床实验室、三种Mueller-Hinton琼脂上,用56株碳青霉烯耐药肠杆菌目细菌评估了四种新上市的氨曲南-阿维巴坦药敏产品(两种梯度扩散法、两种纸片扩散法),以微量肉汤稀释法为参考。所有产品分析性能可接受,梯度扩散法基本一致性高,分类一致性为81.5%–89.3%,差异均为小错误且几乎仅见于折点附近菌株。
要点
- 四种商业氨曲南-阿维巴坦药敏产品性能可接受,支持临床微生物实验室使用。
- 梯度扩散法基本一致性:bioMérieux 92.6%,Liofilchem 89.6%。
- 分类一致性81.5%–89.3%,差异均为小错误,集中于折点附近菌株。
核心结论
- 四种商业氨曲南-阿维巴坦药敏产品与参考微量肉汤稀释法相比分析性能可接受。
- 梯度扩散法显示高基本一致性,所有产品分类一致性为81.5%–89.3%。
- 分类差异均为小错误,且几乎仅发生于折点附近菌株。
研究设计与样本
- 在两家独立临床实验室、三种Mueller-Hinton琼脂制造商条件下评估56株碳青霉烯耐药肠杆菌目细菌。
- 评估四种新上市氨曲南-阿维巴坦药敏产品:两种梯度扩散法(bioMérieux Etest、Liofilchem MIC Test Strip)和两种纸片扩散法(Hardy、Liofilchem)。
- 以微量肉汤稀释法为参考方法,分析基本一致性、分类一致性、错误率和重现性。
- 使用富含不敏感和折点邻近MIC的多样化菌株集合严格评估分类一致性。
主要发现
- 梯度扩散法基本一致性:bioMérieux 92.6%,Liofilchem 89.6%。
- 所有四种产品分类一致性范围为81.5%–89.3%。
- 所有分类差异均为小错误,且几乎仅见于折点邻近菌株。
- 培养基相关变异轻微,质控性能总体高,室内精密度强且跨实验室表现一致。
- 重复和差异测试后,任何产品均未遗留重大或极重大错误。
关键数值与推荐
- 梯度扩散法基本一致性:bioMérieux 92.6%,Liofilchem 89.6%。
- 四种产品分类一致性范围为81.5%–89.3%。
临床怎么用
- 支持临床微生物实验室实施商业氨曲南-阿维巴坦药敏试验产品。
- 折点邻近菌株的分类差异表现为小错误,需关注结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aztreonam-avibactam (AZA) is a recently approved agent active against metallo-β-lactamase-producing Enterobacterales. However, independent evaluations of commercially available antimicrobial susceptibility testing (AST) products remain limited. We evaluated 56 carbapenem-resistant Enterobacterales isolates using four newly available AZA AST products, including two gradient diffusion tests (bioMérieux Etest; Liofilchem MIC Test Strip) and two disk diffusion tests (Hardy, Liofilchem) across three Mueller-Hinton agar manufacturers at two independent clinical laboratories. A diverse isolate collection enriched for nonsusceptible and breakpoint-adjacent MICs was used to rigorously assess categorical agreement (CA). Broth microdilution (BMD) was used as the reference method. Essential agreement (EA), categorical agreement, error rates, and reproducibility were analyzed. All four commercial AST products demonstrated acceptable analytical performance compared with reference BMD. Gradient diffusion demonstrated high EA (bioMérieux 92.6%, Liofilchem 89.6%), whereas CA ranged from 81.5% to 89.3% across all four products. Minor errors accounted for all categorical discrepancies and occurred almost exclusively among breakpoint-adjacent isolates. Medium-related variability was modest, and quality control (QC) performance was generally high, with strong within-site precision and consistent performance across laboratories. This study provides the first comprehensive head-to-head comparison of commercial AZA susceptibility testing products and supports their implementation in clinical microbiology laboratories.IMPORTANCEAztreonam-avibactam is an important new treatment option for infections caused by carbapenem-resistant Enterobacterales, particularly metallo-β-lactamase-producing organisms, but its clinical use requires reliable susceptibility testing. We provide the first head-to-head evaluation of four newly available commercial gradient and disk diffusion products across two independent laboratories and three Mueller-Hinton agar manufacturers. By using a diverse isolate collection enriched for MICs near clinical breakpoints, we also subjected these products to a stringent assessment of categorical agreement. Gradient diffusion demonstrated high essential agreement, and no major or very major errors remained after repeat and discrepancy testing with any product. These findings provide timely, practical evidence to guide clinical laboratories implementing aztreonam-avibactam susceptibility testing.
引用
- Pfeiffer, Subramanya, Kumar, et al. Comparative evaluation of commercial gradient diffusion and disk diffusion tests for aztreonam-avibactam susceptibility testing. J Clin Microbiol. 2026. PMID: 42961037. doi:10.1128/jcm.01124-26
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。